OneOme specializes in pharmacogenomics (PGx), a field of precision medicine that examines how genetic variations influence individual responses to medications. The company’s flagship offering, the RightMed Solution, includes the RightMed Test, which provides healthcare providers with genetic insights to tailor medication decisions based on a patient's unique DNA profile. This approach aims to enhance therapeutic effectiveness and minimize adverse drug reactions, addressing the fact that many medications have response rates as low as 50-75%. By leveraging genetic information, OneOme helps healthcare systems, payers, and providers implement personalized medication strategies that can lead to improved patient outcomes and reduced healthcare costs.

To support the implementation of PGx, OneOme offers a comprehensive suite of tools and services, including secure, HIPAA-compliant portals, clinical consultations, and training programs. Their clinical team curates pharmacogenomic data from scientific literature, FDA guidelines, and clinical studies to ensure that healthcare professionals have access to credible and actionable information. Additionally, OneOme's technology facilitates EHR integration and alerts, streamlining workflows for providers and enhancing access to PGx results. This robust support system empowers healthcare teams to make informed medication decisions, ultimately aiming to optimize patient care and reduce the risk of adverse drug reactions.

United States

OneOme, co-founded by Mayo Clinic, is working to help providers incorporate pharmacogenomics into patient care by offering the RightMed Test and associated tools. The RightMed Test may help providers optimize medication selection for their patients by analyzing and reporting on 27 genes. 

OneOme is privately held, based in Minneapolis, MN. For more information, visit www.oneome.com and follow us here for updates.

OneOme

Company Details